Business Wire

PTC

18.10.2018 12:02:07 CEST | Business Wire | Press release

Share
New Industry Research Shows Augmented Reality Adopters Have Best-in-Class Performance Related to Factory Operations, Service, and Training

PTC (NASDAQ: PTC) today announced from Augmented World Expo (AWE) Europe 2018 the availability of new research in conjunction with Aberdeen Group titled, “How the Best-in-Class Use Augmented Reality for Superior Service Management.” The comprehensive research study and corresponding report identifies significant financial improvements realized by industrial companies embracing augmented reality (AR), and provides best practices for unlocking the potential of the technology across various environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005051/en/

In addition to the report published today, PTC announced exclusive data from Aberdeen that shows that organizations using AR have experienced significant year-over-year business growth and have improved their bottom lines dramatically.

“The rapid pace of the global market, digital transformation, and increasing shortage of highly skilled workers have produced a disruptive threat for businesses,” said Tom Paquin, research analyst, Aberdeen Group. “However, as evidenced by our latest report with PTC, companies that invest in AR, particularly manufacturing and service organizations, have the opportunity to gain a competitive advantage.”

For enterprises, AR can empower workers to understand and interact with the physical and digital worlds, build new skills with reduced training time and cost, and make informed decisions faster. As a result, businesses can unlock increased productivity and improve the effectiveness of training, manufacturing, and service.

“AR is one of the fastest growing segments in the technology market and has been shown to create significant business value for organizations adopting it. Industrial enterprises are keen to improve customer experiences, open up new revenue streams, and disrupt competition by leveraging the new AR capabilities for product and service differentiation,” said Jim Heppelmann, president and CEO, PTC. “Use cases being developed for end customers have a strong focus on service or maintenance instructions, enabling them to reduce machine downtime and maximize product value.”

AWE Europe 2018
PTC and the topic of enterprise AR took center stage today at AWE Europe 2018, the world’s leading AR and VR conference and expo, held October 18-19 in Munich, Germany.

This morning, Mike Campbell, EVP, Augmented Reality Products, PTC, led a keynote session titled, “PTC Vision for Augmented Reality in the Enterprise ,” in which he spoke about the state of AR in the industrial enterprise, reviewed customer use cases, and illustrated the power of AR to fundamentally change the way people work and to allow organizations to re-imagine how to manufacture, sell, operate, and service industrial products.

“Augmented reality can deliver a significant advantage for industrial organizations as part of their overall digital transformation,” said Mr. Campbell. “PTC customers are better leveraging existing investments in CAD, IoT, and digitalization of content through AR experiences, enabling people to visualize and interact with the digital world in the real-time context of their daily work.”

As a Titanium Sponsor of and exhibitor at the event, PTC is showcasing its latest AR solutions – Vuforia Studio, Vuforia Engine, and Vuforia Chalk – as well as distributing copies of the Aberdeen research report at booth 118. PTC is also participating in The International Symposium on Mixed and Augmented Reality (ISMAR) , which runs in conjunction with AWE Europe, in booth 405.

Adoption Under the Vuforia Brand
In line with the data and findings of the Aberdeen report, PTC has experienced substantial growth and adoption across its dedicated AR business unit. Over 60,000 commercial AR apps have been deployed with PTC’s Vuforia® Engine. In addition, more than 14,000 participants have joined PTC’s Vuforia Studio Free Trial program , providing valuable feedback on use case priorities and hardware requirements, and over 550,000 registered developers use Vuforia as their preferred platform to create AR apps.

PTC has leveraged Vuforia to expand the capabilities of its market-leading ThingWorx ® Industrial Innovation Platform, enabling customers to visualize, instruct, guide, and improve interactions with physical things. Aberdeen data released today shows that Internet of Things (IoT) technology is currently a function of 82 percent of all businesses leveraging AR.

Aberdeen Report: “How the Best-in-Class Use Augmented Reality for Superior Service Management”
The Aberdeen report, which investigates service AR use cases of best-in-class organizations versus all other adopters, offers the following highlights:

  • Service organizations using AR have performed significantly better than non-users across customer retention, customer satisfaction, and year-over-year revenue improvement
  • The best-in-class companies have performed, on average, 25 percent better than their peers across performance measurements, including regulatory and SLA compliance
  • 34 percent of best-in-class organizations leverage AR-powered training, 31 percent use on-site guides, and 25 percent are using AR-powered knowledge sharing

To download a copy of the full report, please visit https://www.ptc.com/en/AWE-Europe .

Additional Resources

The adoption by customers of Vuforia AR solutions to date is not indicative of the amount of revenue with respect to any particular period or that customers will continue to adopt or deploy such technologies at any particular rate.

About PTC (NASDAQ: PTC)
PTC helps companies around the world reinvent the way they design, manufacture, operate, and service products in and for a smart, connected world. In 1986 we revolutionized digital 3D design, and in 1998 were first to market with Internet-based product lifecycle management. Today, our leading industrial innovation platform and field-proven solutions enable you to unlock value at the convergence of the physical and digital worlds. With PTC, manufacturers and an ecosystem of partners and developers can capitalize on the promise of the Internet of Things and augmented reality technology today and drive the future of innovation.

PTC.com @PTC Blogs

PTC, Vuforia, ThingWorx, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.

Contact:

PTC Jack McAvoy, 781-370-6143 Corporate Communications jmcavoy@ptc.com

Link:

ClickThru

Social Media:

https://www.facebook.com/PTC.Inc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye